The recovery domain is driven by two complementary mechanisms: angiogenesis/tissue-repair signaling (BPC-157 and TB-500) and anti-inflammatory modulation (KPV). Together they address both the structural side of healing — blood vessel formation, fibroblast migration, collagen deposition — and the systemic side — quieting the inflammatory cascade that slows repair.
This stack is designed for active injury recovery, post-surgical healing, or athletes in high-volume training blocks. Typical run length: 4–8 weeks.
Primary compound — BPC-157 + TB-500 blend
NF-020 (BPC-157 + TB-500) combines two of the most-studied regenerative peptides into a single vial. BPC-157 is the gastric-derived pentadecapeptide with the strongest literature for tendon, ligament, and GI healing. TB-500 (thymosin beta-4 fragment) accelerates cell migration to injury sites and is associated with angiogenesis.
The blend reduces injection frequency (one subq dose vs. two separate ones) without changing pharmacokinetics meaningfully.
Adjunct — KPV
KPV (NF-028) is the C-terminal tripeptide of alpha-MSH with no melanocortin activity but significant anti-inflammatory signaling. It acts downstream of the inflammatory cascade, which means it complements rather than competes with the BPC/TB-500 pair. Daily subcutaneous dosing during the acute phase.
Proposed dosing window
| Compound | Frequency | Published range |
|---|---|---|
| BPC-157 + TB-500 blend | Daily (subq, site of injury) | 500 mcg |
| KPV | Daily |
